Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Carcinoma, Non-Small-Cell Lung 3Neoplasms by Histologic Type 2Myeloproliferative Disorders 2Leukemia, Myeloid 2Hematologic Diseases 2Bone Marrow Diseases 2Small Cell Lung Carcinoma 1Piebaldism 1Malignant Hepatobiliary Neoplasm 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Blast Crisis 1Adenocarcinoma of Lung 1

Interventions

ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Malignant Hepatobiliary Neoplasm × ponatinib × Clear all
NCT02265341 2020-11-25

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Mayo Clinic

Phase 2 Completed
12 enrolled 11 charts
Gastrointestinal

Malignant Hepatobiliary Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡